MTLS status predicts survival benefit from adjuvant chemotherapy in gastric cancer patients treated with neoadjuvant therapy and surgery.

ABSTRACT:

Background

The impact of adjuvant chemotherapy (ACT) on gastric cancer (GC) patients receiving neoadjuvant chemotherapy (NACT) remains unclear. This study aims to evaluate the effect of ACT on survival in patients undergoing curative surgery after NACT.

Methods

Clinical and pathological data of GC patients treated with NACT followed by radical surgery were retrospectively collected. Patients were categorized according to ACT administration. Propensity score matching (PSM) was employed to compare the prognosis between those who received ACT and those who did not.

Results

After cohort selection and PSM, 180 patients with locally advanced GC were included: 116 in the ACT group and 64 in the no ACT group. No significant difference in overall survival (OS) was observed bet

SUBMITTER: Liu D 

PROVIDER: S-EPMC12780721 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature